Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue-serum pairs

Lung Cancer

Volumn 68, Issue 1, 2010, Pages 44-50

  Jordan, K W ^a   Adkins, C B ^a   Su, L ^b   Halpern, E F ^a   Mark, E J ^a   Christiani, D C ^a,b   Cheng, L L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Blood serum; Diagnosis; Lung adenocarcinoma; Lung squamous cell carcinoma; Magic angle spinning; Magnetic resonance spectroscopy; Metabolomics

Indexed keywords

ANALYTIC METHOD; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; HIGH RESOLUTION MAGIC ANGLE SPINNING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; METABOLOMICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM STAGING; SERUM;

EID: 77649187288     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.012     Document Type: Article

References (11)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Report of the NCI Lung Cancer Progress Review Group, http://planning.cancer.gov/pdfprgreports/2001lung.pdf, 2001.
3. Coleman R.E. PET in lung cancer. J Nucl Med 40 (1999) 814-820
4. Higashi K., Matsunari I., Ueda Y., Ikeda R., Guo J., Oguchi M., et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 17 (2003) 1-14
5. Higashi K., Ueda Y., Ayabe K., Sakurai A., Seki H., Nambu Y., et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 21 (2000) 707-714
6. Higashi K., Ueda Y., Yagishita M., Arisaka Y., Sakurai A., Oguchi M., et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 41 (2000) 85-92
7. Hicks R.J., Kalff V., MacManus M.P., Ware R.E., Hogg A., McKenzie A.F., et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42 (2001) 1596-1604
8. Guo J., Higashi K., Yokota H., Nagao Y., Ueda Y., Kodama Y., et al. In vitro proton magnetic resonance spectroscopic lactate and choline measurements, 18F-FDG uptake, and prognosis in patients with lung adenocarcinoma. J Nucl Med 45 (2004) 1334-1339
9. Cheng L.L., Burns M.A., Taylor J.L., He W., Halpern E.F., McDougal W.S., et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 65 (2005) 3030-3034
10. Burns M.A., He W., Wu C.L., and Cheng L.L. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat 3 (2004) 591-598
11. Maillet S., Vion-Dury J., Confort-Gouny S., Nicoli F., Lutz N.W., Viout P., et al. Experimental protocol for clinical analysis of cerebrospinal fluid by high resolution proton magnetic resonance spectroscopy. Brain Res Brain Res Protoc 3 (1998) 123-134